Rizatriptan in the control of migraine symptoms

A.V. Savustyanenko

Abstract


Migraine is a neurovascular disorder that itself disturbs the life of a person, and, in addition, increases the risk of cardiovascular diseases and subclinical brain lesions. Important place in the treatment of migraine belongs to triptans, one of which is rizatriptan. During the administration of triptans, 84 % of patients were satisfied and reported that the treatment was effective, while the same value for the administration of non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, was 37 %, analgesics (including paracetamol) — 26 %, ergotamine — 47 %. It is not surprising that such data entailed the modification of therapeutic algorithms towards triptans. Rizatriptan is serotonin 5-HT1B/1D receptor agonist and shows antimigrenous action due to three main mechanisms: constriction of meningeal vessels, suppression of neurogenic inflammation, reduction of pain transmission. Rizatriptan better relieves headache and restores normal functioning during the first 2 hours of treatment, causes less number of relapses within 24 hours after taking the drug, better relieves pain if relapse occurs, compared to the standard reference drug — sumatriptan. The tolerability of both drugs was the same and clinically acceptable. Pharmacoeconomic analysis revealed the superiority of rizatriptan over ergotamine/caffeine, NSAIDs/analgesics and many other triptans. Rizatriptan has a good evidence base of efficacy and tolerability and continues to be the drug of choice in the treatment of migraine.

Keywords


rizatriptan; migraine

References


Miller S., Matharu M.S. Migraine is underdiagnosed and undertreated // Practitioner. — 2014. — V. 258, № 1774. — P. 19-24.

Lipton R.B., Bigal M.E. Migraine: epidemiology, impact, and risk factors for progression // Headache. — 2005. — V. 45

(Suppl. 1). — P. S3-S13.

Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies / Etminan M., Takkouche B., Isorna F.C., Samii A. // BMJ. — 2005. — V. 330, № 7482. — P. 63.

Correction for full version of this article; Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies // BMJ. — 2005. — V. 330, № 7491. — P. 596.

Migraine and risk of cardiovascular disease in women: prospective cohort study / Kurth T., Winter A.C., Eliassen A.H., Dushkes R. et al. // BMJ. — 2016. — V. 353. — P. i2610.

Migraine as a risk factor for subclinical brain lesions / Kruit M.C., van Buchem M.A., Hofman P.A. et al. // JAMA. — 2004. — V. 291, № 4. — P. 427-434.

A self-administered screener for migraine in primary care: The ID Migraine validation study / Lipton R.B., Dodick D., Sadovsky R. et al. // Neurology. — 2003. — V. 61, № 3. — P. 375-382.

Diagnostic accuracy of the ID Migraine: a systematic review and meta-analysis / Cousins G., Hijazze S., Van de Laar F.A., Fahey T. // Headache. — 2011. — V. 51, № 7. — P. 1140-148.

The International Classification of Headache Disorders, 3rd

edition / Headache Classification Committee of the International Headache Society (IHS) // Cephalalgia. — 2018. — V. 38. — P. 1-211.

Критерии диагностики основных видов первичных головных болей согласно новым изменениям в Международной классификации головных болей (МКГБ), версия 3 бета, 2013 / Лебедева Е.Р., Осипова В.В., Табеева Г.Р., Олесен Е. // Уральский медицинский журнал. — 2014. — № 3. — С. 5-8.

Морозова О.Г. Мигрень: новые международные критерии постановки диагноза и принципы терапии, основанные на доказательной медицине и собственном клиническом опыте // Міжнародний неврологічний журнал. — 2016. — № 3. — С. 131-138.

Практические вопросы ведения пациентов с хронической мигренью. Рекомендации российских экспертов / Латышева Н.В., Филатова Е.Г., Табеева Г.Р. и др. // Нервно-мышечные болезни. — 2015. — Т. 5, № 3. — С. 2-7.

An instrument to assess patient perceptions of satisfaction with acute migraine treatment (EXPERT Study) / Lantéri-Minet M., Massiou H., Romatet S. et al. // Headache. — 2011. — V. 51, № 4. — P. 590-601.

European principles of management of common headache disorders in primary care / European Headache Federation; Lifting The Burden: The Global Campaign to Reduce the Burden of Headache Worldwide; World Health Organization // J. Headache Pain. — 2007. — V. 8 (Suppl. 1). — P. S3-S47.

Evers S., Lisotto C. An Algorithm of Migraine Treatment // European Neurological Review. — 2013. — V. 8, № 2. — P. 149-152.

Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: comparison to the current FDA requirement using the complete rizatriptan study database / Rodgers A.J., Hustad C.M., Cady R.K. et al. // Headache. — 2011. — V. 51, № 3. — P. 356-368.

Canadian Headache Society Guideline: acute drug therapy for migraine headache / Canadian Headache Society Acute Migraine Treatment Guideline Development Group // Can. J. Neurol. Sci. — 2013. — V. 40, № 5 (Suppl. 3). — P. S1-S80.

Brandes J.L., Buchanan T.M., Welch K.M.A. Chapter 26 — Acute treatment of migraine // Handbook of Clinical Neurology. — 2010. — V. 97. — P. 323-336.

Bigal M.E., Krymchantowski A.V., Ho T. Migraine in the triptan era: progresses achieved, lessons learned and future developments // Arq. Neuropsiquiatr. — 2009. — V. 67, № 2B. — P. 559-569.

Göbel H. Efficacy and tolerability of rizatriptan 10 mg compared with sumatriptan 100 mg: an evidence-based analysis // Expert Rev. Neurother. — 2010. — V. 10, № 4. — P. 499-506.

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group / Tfelt-Hansen P., Teall J., Rodriguez F. et al. // Headache. — 1998. — V. 38, № 10. — P. 748-755.

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials / Ferrari M.D., Roon K.I., Lipton R.B., Goadsby P.J. // Lancet. — 2001. — V. 358, № 9294. — P. 1668-1675.

Belsey J.D. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management // J. Clin. Res. — 2003. — V. 4. — P. 105-125.

Restoring migraine sufferers’ ability to function normally: a comparison of rizatriptan and other triptans in randomized trials / Bussone G., D’Amico D., McCarroll K.A. et al. // Eur. Neurol. — 2002. — V. 48, № 3. — P. 172-177.

Belsey J.D. Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials // Curr. Med. Res. Opin. — 2004. — V. 20, № 5. — P. 659-669.

McCormack P.L., Foster R.H. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine // Pharmacoeconomics. — 2005. — V. 23, № 12. — P. 1283-1298.




DOI: https://doi.org/10.22141/2224-0713.2.96.2018.130484

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта